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A 56-year-old nonsmoking Korean woman was diag-
nosed with stage 4 lung adenocarcinoma. Computed tomog-
raphy (CT) scan showed a dominant left lung mass (Figure 1)
with pulmonary, mediastinal, liver, adrenal, bone, and brain
metastases. Erlotinib 150 mg daily and whole brain irradia-
tion were started, and an epithelial growth factor receptor
(EGFR) exon 19 mutation was detected. Symptoms improved
until week 5 when she developed a new fever, worsening skin
rash, and nonproductive cough. Erlotinib was held, and top-
ical cleocin and oral doxycycline 200 mg daily were begun.
Over the next 4 days, cough and dyspnea worsened with fall
of O2 saturation to 92%, prompting repeat CT scan. This
revealed a tumor response; however, new extensive bilateral
ground glass opacities consistent with erlotinib-induced in-
terstitial lung disease (ILD) were noted (Figure 2). No further
diagnostic studies were performed, and prednisone 60 mg
daily was initiated. Fever, cough, and dyspnea improved 3
days later at which time she was placed on 40 mg daily. As
she was not a candidate for current second-generation
EGFR inhibitor trials, she was rechallenged with erlotinib
100 mg daily on day 10 (erlotinib stopped day 0). She
remained afebrile with improved cough, dyspnea, and O2
saturation on room air of 96%. The patient understood the
risks, signed a new informed consent, and was given a
peak flow meter for monitoring. On day 14, prednisone
was decreased to 30 mg daily and doxycycline to 100 mg
daily. On day 21, doxycycline was discontinued, and on
day 28, prednisone was tapered to 20 mg daily. Erlotinib
was increased to 150 mg on day 35 and prednisone tapered
over next 3 weeks. Resolution of pneumonitis was con-
firmed by CT scan on day 60 (Figure 3) receiving full dose
erlotinib off prednisone. Five months later, she had no
further pulmonary complications.
DISCUSSION
Erlotinib is recommended as first-line therapy for pa-
tients with EGFR-mutant lung cancer. ILD is a serious
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FIGURE 1. Initial CT showing dominant left lung mass with
multiple pulmonary nodules. CT, computed tomography.
FIGURE 2. CT scan of a representative section of lung
showing ground glass opacities consistent with erlotinib-in-
duced ILD. CT, computed tomography; ILD, interstitial lung
disease.
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complication with an incidence estimated at 0.8%1 and is
fatal in approximately one third of cases. Permanent discon-
tinuation of erlotinib is recommended along with the use of
corticosteroids and supportive care. As this patient had a
tumor response, we contacted pharmaceutical liaisons and
confirmed there was little guidance on the safety of a rechal-
lenge. In addition, clinical trials with second-generation
EGFR inhibitors exclude patients with drug-associated ILD.
There have been two recent reports describing treatment with
erlotinib after gefitinib-induced ILD,2–3 suggesting it may be
possible to restart EGFR inhibitors in selected patients, es-
pecially those without a smoking history.4 This is, to our
knowledge, the first report of a successful erlotinib rechal-
lenge after erlotinib-induced ILD. The prompt recognition of
ILD allowed early discontinuation of erlotinib and institution
of corticosteroids. We also hypothesize that the antiinflam-
matory properties of doxycycline5 may have contributed to
the rapid resolution of pulmonary symptoms; however, this
would need to be confirmed in a prospective trial. We
propose that patients with EGFR mutations who have been
successfully treated for erlotinib-ILD and are receiving a dose
of prednisone three-fourths 40 mg daily be considered for
future kinase inhibitor treatments and clinical trials.
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FIGURE 3. Improvement in both ILD and the primary lung
mass. ILD, interstitial lung disease.
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